C4 Therapeutics Sees Steady Trading Volume Despite 5.53% Drop in 2023.
March 23, 2023
Trending News ☀️
C4 Therapeutics ($NASDAQ:CCCC) Inc. has seen a steady average trading volume in recent days, despite a slight drop in share prices. On the previous trading day, C4 Therapeutics Inc. closed at $4.16 but dropped to $3.93 at the end of the day, representing a decrease of -5.53%. This represents a significant drop for the company that had been trading within a narrow range for most of the year.
The company’s market capitalization is still a respectable amount and many investors are still confident in the company’s ability to rebound from this short-term stumble. C4 Therapeutics Inc. is also continuing to make strides in its research and development of new treatments for various diseases and health conditions, offering optimism for long-term growth of the company.
Market Price
Despite the overall negative media exposure, C4 Therapeutics stock opened at $4.1 and closed at $4.0 on Tuesday, experiencing a 0.7% decrease from the prior closing price of $4.0. This demonstrates that the company is still able to attract investor interest and stability despite the overall decrease in share prices this year. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for C4 Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 31.1 | -128.18 | -412.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for C4 Therapeutics. More…
| Operations | Investing | Financing |
| -105.94 | 58.42 | 1.15 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for C4 Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 430.84 | 141.61 | 5.91 |
Key Ratios Snapshot
Some of the financial key ratios for C4 Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 13.3% | – | -405.1% |
| FCF Margin | ROE | ROA |
| -358.4% | -25.9% | -18.3% |
Analysis
At GoodWhale, we have closely analyzed the fundamentals of C4 THERAPEUTICS and have assigned it a medium risk rating. We have taken into account various financial and business aspects to determine this rating. Our Risk Ratings feature looks at the balance sheet, cash flow statement and other key financial indicators in order to provide an insight into the financial health of a company. After looking closely at C4 THERAPEUTICS, we have detected two risk signals that require further investigation. To access a more detailed report, register on goodwhale.com. We believe that Risk Ratings are a valuable tool for investors to use when considering potential investments. Our team of experts is committed to providing you with reliable and accurate ratings that can help you make informed decisions about your investments. More…
Peers
C4 Therapeutics Inc is a biopharmaceutical company that focuses on the development of novel small molecule therapies. The company’s main competitors are Annovis Bio Inc, Alk-Abello A/S, and Corbus Pharmaceuticals Holdings Inc. All three companies are engaged in the development of therapies for the treatment of various diseases.
– Annovis Bio Inc ($NYSE:ANVS)
Annovis Bio Inc is a clinical stage pharmaceutical company focused on the development of treatments for Alzheimer’s disease and other neurodegenerative disorders. The company’s lead product candidate, ANVS-401, is a novel small molecule that targets tau protein aggregation, a key driver of neurodegeneration. Annovis is initially targeting the early stage Alzheimer’s market, where there is a high unmet need for effective treatments.
Annovis has a market cap of 98.78M as of 2022. The company’s return on equity (ROE) is -37.92%. This means that for every dollar invested in the company, shareholders are losing 37 cents. The company’s stock price has been volatile in recent years, and it is currently trading near its 52-week low. Given the high risk/reward profile of clinical stage pharmaceutical companies, Annovis is not suitable for risk-averse investors. However, investors with a higher tolerance for risk may find the company’s potential upside attractive.
– Alk-Abello A/S ($LTS:0OIR)
Alk-Abello A/S is a Danish company that produces and sells allergy immunotherapy products. The company was founded in 1929 and has approximately 1,400 employees. The company’s products are sold in more than 60 countries. Alk-Abello A/S has a market cap of 29.51B as of 2022, a Return on Equity of 6.85%. The company’s products are designed to treat a wide range of allergies, including hay fever, pet allergies, dust allergies, and food allergies. The company’s products are available in both prescription and over-the-counter forms.
– Corbus Pharmaceuticals Holdings Inc ($NASDAQ:CRBP)
Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company. The company focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company’s lead product candidate is anabasum, which is in Phase III clinical development for the treatment of dermatomyositis, systemic sclerosis, and cystic fibrosis.
Summary
C4 Therapeutics has seen a decline of 5.53% in its stock price in 2023. Despite this, trading volume has remained steady, suggesting that investors are not overly concerned about the decline. In terms of media coverage, the reports have been largely negative, with few positive analyses being shared.
Nevertheless, analysts have suggested that the company’s long-term prospects remain attractive due to its potential for growth in the pharmaceuticals field. Investing in C4 Therapeutics could be a wise move for those seeking to benefit from a diversified portfolio and the potential rewards associated with investing in a promising biotech company.
